following a full submission
brimonidine (Mirvaso®) is accepted for restricted use within NHS Scotland.
Indication under review: the symptomatic treatment of facial erythema of rosacea in adult patients.
SMC restriction: for use in patients with moderate to severe persistent facial erythema associated with rosacea.
Two identical phase III studies demonstrated that brimonidine 0.33% gel significantly reduced erythema compared with vehicle gel in patients with rosacea.
Download detailed advice177KB (PDF)
- Medicine name:
- brimonidine (Mirvaso)
- SMC ID:
- The symptomatic treatment of facial erythema of rosacea in adult patients.
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Submission type
- Date advice published
- 12 January 2015